HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mullins, D. W. Articles by Engelhard, V. H. Search for Related Content PubMed PubMed Citation Articles by Mullins, D. W. Articles by Engelhard, V. H.

Immune Responses to the HLA-A*0201-Restricted Epitopes of Tyrosinase and Glycoprotein 100 Enable Control of Melanoma Outgrowth in HLA-A*0201-Transgenic Mice¹

Department of Microbiology and Carter Immunology Center, University of Virginia, Charlottesville, VA 22908

Many of the Ags recognized by human melanoma-reactive CTL are derived from proteins that are also expressed in melanocytes. The possibility of self-tolerance to these epitopes has led to questions about their utility for antitumor immunotherapy. To investigate the issue, we established a preclinical model based on transgenic mice expressing a recombinant HLA-A*0201 molecule and B16 melanoma transfected to express this molecule. HLA-A*0201-restricted epitopes from the melanocyte differentiation proteins (MDP) tyrosinase and gp100 are expressed in both tumor cells and melanocytes, and the former is associated with self-tolerance. However, adoptive transfer of tyrosinase or gp100-reactive CTL developed from tolerant mice delayed tumor outgrowth, as did immunization with MDP peptide-pulsed dendritic cells. Protection was enhanced by the use of peptide ligands containing conservative substitutions that were cross-reactive with the original Ags. These data establish that CTL populations reactive against MDP-derived self-Ags can be activated to mount effective antitumor immunity and strongly support their continued development for tumor immunotherapy in humans.

This article has been cited by other articles:

				R. Lengagne, S. Graff-Dubois, M. Garcette, L. Renia, M. Kato, J.-G. Guillet, V. H. Engelhard, M.-F. Avril, J.-P. Abastado, and A. Prevost-Blondel Distinct Role for CD8 T Cells toward Cutaneous Tumors and Visceral Metastases J. Immunol., January 1, 2008; 180(1): 130 - 137. [Abstract] [Full Text] [PDF]

				L. A. Nichols, Y. Chen, T. A. Colella, C. L. Bennett, B. E. Clausen, and V. H. Engelhard Deletional Self-Tolerance to a Melanocyte/Melanoma Antigen Derived from Tyrosinase Is Mediated by a Radio-Resistant Cell in Peripheral and Mesenteric Lymph Nodes J. Immunol., July 15, 2007; 179(2): 993 - 1003. [Abstract] [Full Text] [PDF]

				S. L. Sheasley-O'Neill, C. C. Brinkman, A. R. Ferguson, M. C. Dispenza, and V. H. Engelhard Dendritic Cell Immunization Route Determines Integrin Expression and Lymphoid and Nonlymphoid Tissue Distribution of CD8 T Cells J. Immunol., February 1, 2007; 178(3): 1512 - 1522. [Abstract] [Full Text] [PDF]

				K. M. Hargadon, C. C. Brinkman, S. L. Sheasley-O'Neill, L. A. Nichols, T. N. J. Bullock, and V. H. Engelhard Incomplete Differentiation of Antigen-Specific CD8 T Cells in Tumor-Draining Lymph Nodes J. Immunol., November 1, 2006; 177(9): 6081 - 6090. [Abstract] [Full Text] [PDF]

				A. D. Gritzapis, L. G. Mahaira, S. A. Perez, N. T. Cacoullos, M. Papamichail, and C. N. Baxevanis Vaccination with Human HER-2/neu (435-443) CTL Peptide Induces Effective Antitumor Immunity against HER-2/neu-Expressing Tumor Cells In vivo. Cancer Res., May 15, 2006; 66(10): 5452 - 5460. [Abstract] [Full Text] [PDF]

				E. Galkina, A. Kadl, J. Sanders, D. Varughese, I. J. Sarembock, and K. Ley Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent J. Exp. Med., May 15, 2006; 203(5): 1273 - 1282. [Abstract] [Full Text] [PDF]

				D. W. Mullins and V. H. Engelhard Limited infiltration of exogenous dendritic cells and naive T cells restricts immune responses in peripheral lymph nodes. J. Immunol., April 15, 2006; 176(8): 4535 - 4542. [Abstract] [Full Text] [PDF]

				N. Casares, M. O. Pequignot, A. Tesniere, F. Ghiringhelli, S. Roux, N. Chaput, E. Schmitt, A. Hamai, S. Hervas-Stubbs, M. Obeid, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death J. Exp. Med., December 19, 2005; 202(12): 1691 - 1701. [Abstract] [Full Text] [PDF]

				P. J. Tacken, I. J. M. de Vries, K. Gijzen, B. Joosten, D. Wu, R. P. Rother, S. J. Faas, C. J. A. Punt, R. Torensma, G. J. Adema, et al. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody Blood, August 15, 2005; 106(4): 1278 - 1285. [Abstract] [Full Text] [PDF]

				D. W. Mullins, S. L. Sheasley, R. M. Ream, T. N.J. Bullock, Y.-X. Fu, and V. H. Engelhard Route of Immunization with Peptide-pulsed Dendritic Cells Controls the Distribution of Memory and Effector T Cells in Lymphoid Tissues and Determines the Pattern of Regional Tumor Control J. Exp. Med., October 6, 2003; 198(7): 1023 - 1034. [Abstract] [Full Text] [PDF]